Theralase Technologies Inc. (CVE:TLT – Get Free Report)’s share price dropped 12.3% during trading on Tuesday . The company traded as low as C$0.25 and last traded at C$0.25. Approximately 225,401 shares were traded during trading, a decline of 55% from the average daily volume of 495,644 shares. The stock had previously closed at C$0.29.
Theralase Technologies Trading Down 10.5%
The stock has a market capitalization of C$67.55 million, a P/E ratio of -14.17 and a beta of -0.35. The company has a current ratio of 1.91, a quick ratio of 3.40 and a debt-to-equity ratio of 14.85. The business has a 50-day moving average price of C$0.18 and a two-hundred day moving average price of C$0.19.
About Theralase Technologies
Theralase Technologies Inc, a clinical stage pharmaceutical company, engages in the research and development of light activated photo dynamic compounds (PDCs) and their associated drug formulations to treat cancers, bacteria, and viruses in Canada, the United States, and internationally. It also designs, develops, manufactures, and markets patented and proprietary super-pulsed laser technology for the healing of chronic knee pain, as well as for off-label use to heal various nerve, muscle, and joint conditions.
Featured Stories
- Five stocks we like better than Theralase Technologies
- Elon Taking SpaceX Public! $100 Pre-IPO Opportunity!
- How a Family Trust May Be Able To Help Preserve Your Wealth
- A U.S. “birthright” claim worth trillions – activated quietly
- This stock gets a 94 out of 100
- First Time Since 2007: All Warnings Active
Receive News & Ratings for Theralase Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theralase Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
